『The Financial Reality of Bispecific Antibodies: What It Takes to Build and Sustain a Program』のカバーアート

The Financial Reality of Bispecific Antibodies: What It Takes to Build and Sustain a Program

The Financial Reality of Bispecific Antibodies: What It Takes to Build and Sustain a Program

無料で聴く

ポッドキャストの詳細を見る

【Amazonプライム会員限定】今ならプレミアムプランが4か月 月額99円。

10月19日まで。※適用条件あり
As oncology therapies become increasingly complex and high cost, cancer programs are being pushed to rethink how financial, operational, and clinical decisions come together in practice. In this episode, CANCER BUZZ sits down with Sarah Hudson-DiSalle, Assistant Director of Infusion Reimbursement Services, to explore the real-world financial landscape of bispecific antibodies (BsAbs), focusing on how organizations evaluate readiness, navigate uncertainty, and manage financial risk. Through a practical, system-level lens, this conversation highlights where challenges emerge, how institutions are approaching implementation, and what lessons may translate across care settings. "Helping leadership get comfortable [with] the financial risk kind of starts with that clear communication and education on the drug as a whole. Getting them to see past just the dollar tag of the drug. It's important to provide kind of that balanced view of both clinical value and financial implication, so they can make a really informed decision of how that impacts patient care, their community, and the institution as a whole." - Sarah Hudson-DiSalle, PharmD, RPh, FACCC "I've learned that it's important having a clear plan from the beginning, making sure that you know who your stakeholders are, aligning those around the plan, and having consistent monitoring for outcomes for implementation of who's your customer. Regardless of the organization's size, that success rate really starts with understanding the clinical, the operational, the financial implications of the new therapies, and then defining your roles, responsibilities, and processes up front, and who needs to know that information." - Sarah Hudson-DiSalle, PharmD, RPh, FACCC In partnership with HOPA, APSHO, LRF.  This program was made possible with support from AbbVie, Amgen, Pfizer, Johnson & Johnson, Genentech.  Guest:  Sarah Hudson-DiSalle, PharmD, RPh, FACCC Assistant Director of Infusion Reimbursement Services The James Cancer Hospital and Wexner Medical Center at the Ohio State University Department of Pharmacy Resources:   A Blueprint for Successful Integration of Bispecific Antibodies    Delivery Models for Administering T-Cell-Engaging Bispecific Antibodies   Delivering T-Cell-Engaging Bispecific Antibodies: Frequently Asked Questions (FAQ)   ACCC Office Hours Recording - Bispecific Antibodies: One BiTE at a Time      Bispecific Antibodies Checklist for Community Providers   Using Bispecific Antibodies in Community Practice: Challenges and Opportunities   Expanding Access to Cellular and Bispecific Therapies: Considerations and Recommendations  
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません